% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Johann:128845,
author = {P. Johann$^*$ and S. Erkek$^*$ and M. Zapatka$^*$ and K.
Kerl and I. Buchhalter and V. Hovestadt$^*$ and D. Jones$^*$
and D. Sturm$^*$ and C. Hermann and M. Segura Wang and A.
Korshunov$^*$ and M. Rhyzova and S. Gröbner$^*$ and S.
Brabetz$^*$ and L. Chavez$^*$ and S. Bens and S.
Gröschel$^*$ and F. Kratochwil$^*$ and A. Wittmann$^*$ and
L. Sieber$^*$ and C. Geörg and S. Wolf$^*$ and K. Beck$^*$
and F. Oyen and D. Capper$^*$ and P. van Sluis and R.
Volckmann and J. Koster and R. Versteeg and A. von
Deimling$^*$ and T. Milde$^*$ and O. Witt$^*$ and A. E.
Kulozik and M. Ebinger and T. Shalaby and M. Grotzer and D.
Sumerauer and J. Zamecnik and J. Mora and N. Jabado and M.
D. Taylor and A. Huang and E. Aronica and A. Bertoni$^*$ and
B. Radlwimmer$^*$ and T. Pietsch and U. Schüller and R.
Schneppenheim and P. A. Northcott$^*$ and J. O. Korbel and
R. Siebert and M. C. Frühwald and P. Lichter$^*$ and R.
Eils$^*$ and A. Gajjar and M. Hasselblatt and S. Pfister$^*$
and M. Kool$^*$},
title = {{A}typical {T}eratoid/{R}habdoid {T}umors {A}re {C}omprised
of {T}hree {E}pigenetic {S}ubgroups with {D}istinct
{E}nhancer {L}andscapes.},
journal = {Cancer cell},
volume = {29},
number = {3},
issn = {1535-6108},
address = {Cambridge, Mass.},
publisher = {Cell Press},
reportid = {DKFZ-2017-04858},
pages = {379 - 393},
year = {2016},
abstract = {Atypical teratoid/rhabdoid tumor (ATRT) is one of the most
common brain tumors in infants. Although the prognosis of
ATRT patients is poor, some patients respond favorably to
current treatments, suggesting molecular inter-tumor
heterogeneity. To investigate this further, we genetically
and epigenetically analyzed 192 ATRTs. Three distinct
molecular subgroups of ATRTs, associated with differences in
demographics, tumor location, and type of SMARCB1
alterations, were identified. Whole-genome DNA and RNA
sequencing found no recurrent mutations in addition to
SMARCB1 that would explain the differences between
subgroups. Whole-genome bisulfite sequencing and H3K27Ac
chromatin-immunoprecipitation sequencing of primary tumors,
however, revealed clear differences, leading to the
identification of subgroup-specific regulatory networks and
potential therapeutic targets.},
keywords = {Chromosomal Proteins, Non-Histone (NLM Chemicals) /
DNA-Binding Proteins (NLM Chemicals) / SMARCB1 Protein (NLM
Chemicals) / SMARCB1 protein, human (NLM Chemicals) /
Transcription Factors (NLM Chemicals)},
cin = {B062 / B060 / G380 / G340 / G240 / G100 / B069},
ddc = {610},
cid = {I:(DE-He78)B062-20160331 / I:(DE-He78)B060-20160331 /
I:(DE-He78)G380-20160331 / I:(DE-He78)G340-20160331 /
I:(DE-He78)G240-20160331 / I:(DE-He78)G100-20160331 /
I:(DE-He78)B069-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:26923874},
doi = {10.1016/j.ccell.2016.02.001},
url = {https://inrepo02.dkfz.de/record/128845},
}